Table 5 Synopsis of selected phase II chemotherapy trials performed for recurrent GBM
Reference | Intervention | Pts. (n) | chemo-naïve (%) | PFS6 mo (%) | PFS (weeks) |
|---|---|---|---|---|---|
Brandes (2004) [23] | BCNU ± re-resection | 40 | 100 | 17.5 | 13.3 |
Fine (2003) [25] | BCNU + thalidomide | 38 | 50 | 27 | 14.9 |
Prados (2004) [26] | BCNU + TMZ (single dose) | 38 | 89.5 | 21 | 11 |
Brandes (2004) [24] | BCNU + irinotecan | 42 | 0 | 30.3 | 17 |
Yung (2000) [46] | TMZ (5/28) vs. procarbazine | 112 | 35 | 21 vs. 8 | 12.4 |
Brada (2001) [47] | TMZ (5/28) | 128 | 29 | 18 | 8 |
Brandes (2002) [48] | TMZ (5/28) | 42 | 0 | 24 | 11.7 |
Chang (2004) [49] | TMZ (5/28) | 142 | 56 | 18 | 10 |
Wick (2007) [50] | TMZ (7/14) | 64 | 36 | 43.8 | 24 |
Perry (2010) [51] | TMZ (continuous) | 91 | NR | 23.9 | 7–15 |
Kappelle (2001) [52] | PCV | 63 | 68.2 | 29 | 13 |
Wong (1999) [53] | historical controls | 225 | NR | 15 | 9 |